

Idiopathic Pulmonary Fibrosis (IPF)

**Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03208933 ML39355

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03208933 ML39355**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 40 Years & ≤ 80 Years

**Healthy Volunteers**  
No

---